Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.32 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587098 | 0.88 | ARG1 (0.33) | ARG1ARG2 | |
| SCHEMBL4588442 | 0.82 | MAPT (0.35) | TLR2MEN1KMT2AALOX15 | |
| SCHEMBL4586012 | 0.81 | NOD1 (0.38) | — | |
| SCHEMBL5148905 | 0.76 | GRM8 (0.37) | KMT2AALOX15 | |
| SCHEMBL4588024 | 0.76 | BHMT (0.33) | ARG1ARG2 | |
| SCHEMBL4618533 | 0.75 | PTGS1 (0.33) | ARG1ARG2 | |
| SCHEMBL4587301 | 0.74 | ARG1 (0.35) | ARG1ARG2 | |
| SCHEMBL4587534 | 0.74 | ALDH1A1 (0.34) | ARG1ARG2 | |
| SCHEMBL13396485 | 0.73 | MEN1 (0.41) | TLR2MEN1KMT2ACYP2C9ALOX15 | |
| SCHEMBL13396359 | 0.72 | CA2 (0.43) | TLR2MEN1KMT2ACYP2C9ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | TLR2 2383/4885ARG1 73/4885ARG2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.